SIGA Technologies, Inc.
- Home
- Companies
- SIGA Technologies, Inc.
- Products
- TPOXX - Injection for Smallpox
TPOXX - Injection for Smallpox
SIGA has developed TPOXX® Injection, an intravenous (IV) formulation of TPOXX® for those patients who are too sick or unable to swallow oral capsules. SIGA completed clinical trials for the IV formulation with funding from the Biomedical Advanced Research and Development Authority (BARDA). In April 2021, SIGA submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for IV TPOXX®. It was formally approved by FDA in May 2022.